Controversies surrounding iron chelation therapy for MDS

Blood Reviews

Volumn 25, Issue 1, 2011, Pages 17-31

  Leitch, Heather A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Iron chelation therapy; Iron overload; MDS; Myelodysplastic syndrome

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN; GLUTAMINE; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE; VITAMIN D;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BETA THALASSEMIA; CAUSE OF DEATH; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CYTOPENIA; ENDOCRINE DISEASE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GLUCOSE TOLERANCE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LIVER DISEASE; LIVER FIBROSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHELATION THERAPY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 78649903132     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.09.003     Document Type: Article

References (172)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
2. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
3. Kantarjian H.M., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Development and validation of a new prognostic model for myelodysplastic syndrome (MDS) that accounts for events not considered by the international prognostic scoring system (IPSS). Blood 2008, 112(11):236-237a.
4. Williamson P.J., Kruger A.R., Reynolds P.J., Hamblin T.J., Oscier D.G. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994, 87(4):743-745.
5. Schiffer C.A. Clinical issues in the management of patients with myelodysplasia. Hematol Am Soc Hematol Educ Program 2006, 205-210.
6. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(6):1037-1046.
7. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106(8):1794-1803.
8. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352(6):549-557.
9. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20(10):2429-2440.
10. Sekeres M.A., Fu A.Z., Maciejewski J.P., Golshayan A.R., Kalaycio M.E., Kattan M.W. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 2007, 109(6):1125-1132.
11. Porter J.B. Practical management of iron overload. Br J Haematol 2001, 115(2):239-252.
12. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(30):7594-7603.
13. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91(12):1588-1590.
14. Sanz G., Nomdedeu B., Such E., Bernal T., Belkaid M., Ardanaz T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112(11):238-239a.
15. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331(9):574-578.
16. Leitch H.A., Leger C.S., Goodman T.A., Wong K.K., Wong D.H.C., Ramadan K.M., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2(3):205-211.
17. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010, 34(7):864-870.
18. Fox F., Kundgen A., Nachtkamp K., Strupp C., Haas R., Germing U., et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 2009, 114(22):694a.
19. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112(1):45-52.
20. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109(8):1536-1542.
21. Kao J.M., McMillan A., Greenberg P.L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008, 83(10):765-770.
22. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100(21):1542-1551.
23. Gupta P., LeRoy S.C., Luikart S.D., Bateman A., Morrison V.A. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999, 23(10):953-959.
24. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87(12):1286-1306.
25. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120(2):187-200.
26. Jansen A.J., Essink-Bot M.L., Beckers E.A., Hop W.C., Schipperus M.R., Van Rhenen D.J. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003, 121(2):270-274.
27. Patel K.V., Harris T.B., Faulhaber M., Angleman S.B., Connelly S., Bauer D.C., et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 2007, 109(11):4663-4670.
28. Oliva E.N., Dimitrov B.D., Benedetto F., D'Angelo A., Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005, 29(10):1217-1219.
29. Goldberg S.L., Mody-Patel N., Warnock N. Prevalence of cardiac disease among a US medicare population with myelodysplastic syndromes. Leuk Res 2007, 31(Supplement 1):S103.
30. Schafer A.I., Cheron R.G., Dluhy R., Cooper B., Gleason R.E., Soeldner J.S., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304(6):319-324.
31. Cazzola M., Barosi G., Gobbi P.G., Invernizzi R., Riccardi A., Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988, 71(2):305-312.
32. Jaeger M., Aul C., Sohngen D., Germing U., Schneider W. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes. Beitr Infusionsther 1992, 30:464-468.
33. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331(9):567-573.
34. Davis B.A., Porter J.B. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000, 95(4):1229-1236.
35. Gabutti V., Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996, 95(1):26-36.
36. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112(2):219-230.
37. Cazzola M., Della Porta M.G., Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2008, 166-175.
38. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006, 29-35:507.
39. Britton R.S., Leicester K.L., Bacon B.R. Iron toxicity and chelation therapy. Int J Hematol 2002, 76(3):219-228.
40. Chen J., Lopez J.A. Interactions of platelets with subendothelium and endothelium. Microcirculation 2005, 12(3):235-246.
41. Hellstrom-Lindberg E., Schmidt-Mende J., Forsblom A.M., Christensson B., Fadeel B., Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001, 112(3):714-726.
42. Epling-Burnette P.K., List A.F. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009, 16(2):70-76.
43. Nearman Z.P., Szpurka H., Serio B., Warshawksy I., Theil K., Lichtin A., et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007, 82(12):1076-1079.
44. Varkonyi J., Tarkovacs G., Karadi I., Andrikovics H., Varga F., Varga F., et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003, 109(2):64-67.
45. Steensma D.P., Viprakasit V., Hendrick A., Goff D.K., Leach J., Gibbons R.J., et al. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. Blood 2004, 103(4):1518-1520.
46. Calzolari A., Oliviero I., Deaglio S., Mariani G., Biffoni M., Sposi N.M., et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis 2007, 39(1):82-91.
47. Chan L.S.A., Buckstein R., Reis M.D., Chesney A., Lam A., Cheung M.C., et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML?. Blood 2008, 112(11):928a.
48. Sallmyr A., Fan J., Rassool F.V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008, 270(1):1-9.
49. Kornblau S.M., Thall P.F., Estrov Z., Walterscheid M., Patel S., Theriault A., et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999, 5(7):1758-1766.
50. Padua R.A., Guinn B.A., Al-Sabah A.I., Smith M., Taylor C., Pettersson T., et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998, 12(6):887-892.
51. Rassool F.V., Gaymes T.J., Omidvar N., Brady N., Beurlet S., Pla M., et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?. Cancer Res 2007, 67(18):8762-8771.
52. Hann H.W., Stahlhut M.W., Blumberg B.S. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 1988, 48(15):4168-4170.
53. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104(5):1450-1458.
54. Jiang Y., Xue Z.H., Shen W.Z., Du K.M., Yan H., Yu Y., et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 2005, 19(7):1239-1247.
55. Eberhard Y., McDermott S.P., Wang X., Gronda M., Venugopal A., Wood T.E., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114(14):3064-3073.
56. Fu D., Richardson D.R. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007, 110(2):752-761.
57. Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med;207(4):731-750.
58. Richardson D.R. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 2005, 12(23):2711-2729.
59. Greene B.T., Thorburn J., Willingham M.C., Thorburn A., Planalp R.P., Brechbiel M.W., et al. Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem 2002, 277(28):25568-25575.
60. Liang S.X., Richardson D.R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 2003, 24(10):1601-1614.
61. Ohyashiki J.H., Kobayashi C., Hamamura R., Okabe S., Tauchi T., Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009, 100(5):970-977.
62. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007, 42(10):830-836.
63. Zacharski L.R., Chow B.K., Howes P.S., Shamayeva G., Baron J.A., Dalman R.L., et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008, 100(14):996-1002.
64. Moore A.B., Shannon J., Chen C., Lampe J.W., Ray R.M., Lewis S.K., et al. Dietary and stored iron as predictors of breast cancer risk: a nested case-control study in Shanghai. Int J Cancer 2009, 125(5):1110-1117.
65. Cermak J. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin 2006, 30(1):105-112.
66. St Pierre T.G., Clark P.R., Chua-anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105(2):855-861.
67. Chacko J., Pennell D.J., Tanner M.A., Hamblin T.J., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007, 138(5):587-593.
68. Di Tucci A.A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93(9):1385-1388.
69. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007, 82(11):1013-1016.
70. Buja L.M., Roberts W.C. Iron in the heart. Etiology and clinical significance. Am J Med 1971, 51(2):209-221.
71. Gao X., Campian J.L., Qian M., Sun X.F., Eaton J.W. Mitochondrial DNA damage in iron overload. J Biol Chem 2009, 284(8):4767-4775.
72. Brittenham G.M., Farrell D.E., Harris J.W., Feldman E.S., Danish E.H., Muir W.A., et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982, 307(27):1671-1675.
73. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102(7):2670-2677.
74. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007, 78(6):487-494.
75. Chee C.E., Steensma D.P., Wu W., Hanson C.A., Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008, 83(8):611-613.
76. Tefferi A., Mesa R.A., Pardanani A., Hussein K., Schwager S., Hanson C.A., et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009, 84(5):265-267.
77. Leitch H.A., Goodman T.A., Wong K.K., Vickars L.M., Galbraith P.F., Leger C.S. Improved survival in patients with Myelodysplastic Syndrome (MDS) receiving iron chelation therapy. Blood 2006, 108:78a.
78. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007, 31(Suppl 3):S7-S9.
79. Rose C., Brechignac S., Vassilief D., Beyne-Rauzy O., Stamatoullas A., Larbaa D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 2007, 110(11):80-1a.
80. Raptis A., Duh M.S., Wang S.T., Dial E., Fanourgiakis I., Fortner B., et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010, 50(1):190-199.
81. Delea T.E., Hagiwara M., Phatak P.D. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009, 25(1):139-147.
82. Della Porta M.G., Kuendgen A., Malcovati L., Zipperer E., Pascutto C., Travaglino E., et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood 2008, 112(11):925-6a.
83. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89(3):739-761.
84. Glickstein H., El R.B., Link G., Breuer W., Konijn A.M., Hershko C., et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006, 108(9):3195-3203.
85. Gattermann N., Schmid M., Guerci-Bresler A., Della Porta M., Taylor K., Habr D., et al. Correlation between deceased serum ferritin and improved liver transaminases during deferasirox (Exjade) treatment in iron-overloaded patients with myelodysplastic syndromes. Blood 2010, 114(11):1462-1463a.
86. Del Río Garma J., Fernandez L.C., Fonrodona B.F.J. Desferrioxamine in the treatment of myelodysplastic syndromes. Haematologica 1997, 82(5):639-640.
87. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94(2):288-299.
88. Jensen P.D., Jensen I.M., Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992, 80(1):121-124.
89. Messa E., Cilloni D., Messa F., Arruga F., Roetto A., Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008, 120(2):70-74.
90. Okabe H., Suzuki T., Omori T., Mori M., Uehara E., Hatano K., et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki 2009, 50(11):1626-1629.
91. Badawi M.A., Vickars L.M., Chase J.M., Leitch H.A. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol 2010, 164045.
92. List A.F., Baer M.R., Steensma D., Raza A., Esposito B., Virkus J., et al. Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 2008, 112(11):523a.
93. Smeets M.E., Vreugdenhil G., Holdrinet R.S. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996, 51(3):243-244.
94. Di Tucci A.A., Murru R., Alberti D., Rabault B., Deplano S., Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007, 78(6):540-542.
95. Park S.J., Han C.W. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008, 23(2):320-323.
96. Ghoti H., Amer J., Winder A., Rachmilewitz E., Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007, 79(6):463-467.
97. Rachmilewitz E., Merkel D., Ghoti H., Amer J., Nagler A., Perez-Avraham G., et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood 2008, 112(11):924-5a.
98. Hartmann J., Sinzig U., Wulf G., Truemper L.H., Braulke F., Konietschke F., et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood 2008, 11:932a.
99. Szuber N., Buss J.L., Soe-Lin S., Felfly H., Trudel M., Ponka P. Alternative treatment paradigm for thalassemia using iron chelators. Exp Hematol 2008, 36(7):773-785.
100. Cortelezzi A., Cattaneo C., Sarina B., Cristiani S., Pomati M., Silvestris I., et al. Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes. Leuk Res 2000, 24(2):129-137.
101. Messa E., Defilippi I., Roetto A., Messa F., Arruga F., Carturan S., et al. Deferasirox is the only iron chelator acting as a potent NFKB inhibitor in myelodysplastic syndromes. Blood 2008, 112(11):923a.
102. Ren X., Dorrington K.L., Maxwell P.H., Robbins P.A. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J Appl Physiol 2000, 89(2):680-686.
103. Remacha AF, Arrizabalaga B, Del Canizo C, Sanz G, Villegas A. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol;89(2):147-154.
104. Giagounidis A, Heptinstall K, Jasmin D, Leto di Priolo S, Ille S, Fenaux P. Detection and Treatment of Iron Overload in Red Blood Cell (RBC) Transfusion-Dependent Myelodysplastic Syndromes (MDS): A European Survey. Blood 2009 ASH Annual Meeting abstract 4830.
105. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114(26):5251-5255.
106. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Malcovati L., Angelucci E., Van Lint M.T., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic sterm cell transplantation: a GITMO study. Haematologica 2010, 95(3):476-484.
107. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109(10):4586-4588.
108. Pullarkat V., Blanchard S., Tegtmeier B., Dagis A., Patane K., Ito J., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transpl 2008, 42(12):799-805.
109. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Ritz J., et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl 2008, 14(1):28-35.
110. Sorror M.L., Storer B.E., Schoch G., Sandmaier B.M., Martin P.J., Scott B.L., et al. Low albumin, high ferritin, and thrombocytopenia before transplant predict non-relapse mortality (NRM) independent of the hematopoietic cell transplantation comorbidity index (HCT-CI). Blood 2009, 114(22):271a.
111. Platzbecker U., Bornhauser M., Germing U., Stumpf J., Scott B.L., Kroger N., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transpl 2008, 14(11):1217-1225.
112. Altes A., Remacha A.F., Sarda P., Baiget M., Sureda A., Martino R., et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007, 86(6):443-447.
113. Mahindra A., Bolwell B., Sobecks R., Rybicki L., Pohlman B., Dean R., et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transpl 2008, 14(11):1239-1244.
114. Kim Y.R., Kim J.S., Cheong J.W., Song J.W., Min Y.H. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol 2008, 120(3):182-189.
115. Mahindra A., Sobecks R., Rybicki L., Pohlman B., Dean R., Andresen S., et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transpl 2009.
116. Mattiuzi G., Amin H.M., Kantarjian H., Garcia-Manero G., Cortes J. Baseline serum ferritin predicts rate of infection in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 2009, 114(22):644a.
117. Altes A., Remacha A.F., Sureda A., Martino R., Briones J., Canals C., et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transpl 2002, 29(12):987-989.
118. Kataoka K., Nannya Y., Hangaishi A., Imai Y., Chiba S., Takahashi T., et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2009, 15(2):195-204.
119. Ozyilmaz E., Aydogdu M., Sucak G., Aki S.Z., Ozkurt Z.N., Yegin Z.A., et al. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transpl 2010, 45(10):1527-1533.
120. Maradei S.C., Maiolino A., de Azevedo A.M., Colares M., Bouzas L.F., Nucci M. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009, 114(6):1270-1275.
121. Lee J.W., Kang H.J., Kim E.K., Kim H., Shin H.Y., Ahn H.S. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transpl 2009, 44(12):793-797.
122. Evens A.M., Mehta J., Gordon L.I. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transpl 2004, 34(7):561-571.
123. Kontoghiorghes G.J., Weinberg E.D. Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 1995, 9(1):33-45.
124. van Asbeck B.S., Marx J.J., Struyvenberg A., Verhoef J. Functional defects in phagocytic cells from patients with iron overload. J Infect 1984, 8(3):232-240.
125. von Bonsdorff L., Sahlstedt L., Ebeling F., Ruutu T., Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 2003, 37(1):45-51.
126. Rose C., Ernst O., Hecquet B., Maboudou P., Renom P., Noel M.P., et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica 2007, 92(6):850-853.
127. Storey J.A., Connor R.F., Lewis Z.T., Hurd D., Pomper G., Keung Y.K., et al. The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol 2009, 2:44.
128. Armand P., Rhodes J., Kim H., Cutler C., Ho V.T., Koreth J., et al. A prospective study of iron overload in patients undergoing ablative stem cell transplantation. Blood 2009, 114(22):1293a.
129. Au W.Y., Lam W.M., Chu W.C., Tam S., Wong W.K., Pennell D.J., et al. A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels. Transpl Proc 2007, 39(10):3369-3374.
130. Iqbal M., Creger R.J., Fox R.M., Cooper B.W., Jacobs G., Stellato T.A., et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management. Bone Marrow Transpl 1996, 17(4):655-662.
131. Azar N., Valla D., Abdel-Samad I., Hoang C., Fretz C., Sutton L., et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation 1996, 62(1):56-61.
132. Strasser S.I., Sullivan K.M., Myerson D., Spurgeon C.L., Storer B., Schoch H.G., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999, 93(10):3259-3266.
133. Sahlstedt L., Ebeling F., von Bonsdorff L., Parkkinen J., Ruutu T. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001, 113(3):836-838.
134. Sahlstedt L., von Bonsdorff L., Ebeling F., Parkkinen J., Juvonen E., Ruutu T. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur J Haematol 2009, 83(5):455-459.
135. Harrison P., Neilson J.R., Marwah S.S., Madden L., Bareford D., Milligan D.W. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol 1996, 49(10):853-856.
136. Sahlstedt L., von Bonsdorff L., Ebeling F., Ruutu T., Parkkinen J. Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients. Br J Haematol 2002, 119(2):547-553.
137. Chaston T.B., Watts R.N., Yuan J., Richardson D.R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin Cancer Res 2004, 10(21):7365-7374.
138. Lewandowski D, Barroca V, Duconge F, Bayer J, Van Nhieu JT, Pestourie C, et al. In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. Blood;115(3):443-452.
139. Kanamori H., Tachibana T., Takasaki H., Tanaka M., Ishigatsubo Y., Maruta A. Elevated serum ferritin predicts the delay of engraftment and high incidence of blood stream infection within 100 days after allogeneic hematopoietic stem cell transplantation. Blood 2009, 114:467a.
140. Brown S.A., Goringe A., Fegan C., Davies S.V., Giddings J., Whittaker J.A., et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transpl 1998, 22(3):281-284.
141. Goringe A.P., Brown S., O'Callaghan U., Rees J., Jebb S., Elia M., et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transpl 1998, 21(8):829-832.
142. Colombo A.A., Alessandrino E.P., Bernasconi P., Arcese G.W., Rabusin M., Bacigalupo A., et al. N-acetylcysteine in the treatment of steroid-resistant acute graft-versus-host-disease: preliminary results. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Transplantation 1999, 68(9):1414-1416.
143. Busca A, Falda M, Manzini P, D'Antico S, Valfre A, Locatelli F, et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant;16(1):115-122.
144. Kamble R.T., Selby G.B., Mims M., Kharfan-Dabaja M.A., Ozer H., George J.N. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2006, 12(5):506-510.
145. Majhail N.S., Lazarus H.M., Burns L.J. A prospective study of iron-overload management in allogeneic hematopoietic-cell transplant survivors. Biol Blood Marrow Transpl 2010, 16(6):832-837.
146. McKay P.J., Murphy J.A., Cameron S., Burnett A.K., Campbell M., Tansey P., et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transpl 1996, 17(1):63-66.
147. Tomas J.F., Pinilla I., Garcia-Buey M.L., Garcia A., Figuera A., de Soria VGG Gomez-Garcia, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transpl 2000, 26(6):649-655.
148. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.
149. Gattermann N., Porter J., Lopes L.F., Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 2005, 19(Suppl 1):18-25.
150. Trial NCT00654589 http://www.clinicaltrials.gov.
151. Wang R., Gross C.P., Halene S., Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009, 33(12):1594-1598.
152. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40(5):373-383.
153. Sabin S.L., Rosenfeld R.M., Sundaram K., Har-el G., Lucente F.E. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 1999, 78(8):578, 581-4.
154. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106(8):2912-2919.
155. Sorror M.L., Sandmaier B.M., Storer B.E., Maris M.B., Baron F., Maloney D.G., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25(27):4246-4254.
156. Zipperer E., Pelz D., Nachtkamp K., Kuendgen A., Strupp C., Gattermann N., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94(5):729-732.
157. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol;21(1):114-9.
158. Della Porta M.G., Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica 2009, 94(5):602-606.
159. Gabrilove J., Paquette R., Lyons R.M., Mushtaq C., Sekeres M.A., Tomita D., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142(3):379-393.
160. Buckstein R., Alibhai S., Lam A., Zhang L., Mamedov A., Cheung M.C., et al. Transfusion dependence and low hemoglobin have the greatest impact on quality of life (QOL) in MDS patients - a tertiary care cross sectional and longitudinal study. Blood 2009, 114(22):986-7a.
161. Cabantchik Z.I., Breuer W., Zanninelli G., Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005, 18(2):277-287.
162. Cohen A.R. New advances in iron chelation therapy. Hematol Am Soc Hematol Educ Program 2006, 42-47.
163. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?. Hematol Am Soc Hematol Educ Program 2009, 664-672.
164. Suzuki T., Tomonaga M., Miyazaki Y., Nakao S., Ohyashiki K., Matsumura I., et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 2008, 88(1):30-35.
165. Valent P., Krieger O., Stauder R., Wimazal F., Nosslinger T., Sperr W.R., et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 2008, 38(3):143-149.
166. Greenberg P.L., Baer M.R., Bennett J.M., Bloomfield C.D., De Castro C.M., Deeg H.J., et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4(1):58-77.
167. Mittelman M., Lugassy G., Merkel D., Tamary H., Sarid N., Rachmilewitz E., et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J 2008, 10(5):374-376.
168. Wells R.A., Leber B., Buckstein R., Lipton J.H., Hasegawa W., Grewal K., et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res 2008, 32(9):1338-1353.
169. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008, 88(1):24-29.
170. Leitch H.A. Iron chelation therapy in MDS: does it improve survival?. Leuk Res 2010, 34(7):852-853.
171. Leitch H.A., Chase J.M., Goodman T.A., Ezzat H., Rollins M.D., Wong D.H., et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol 2010, 28(1):40-48.
172. Leitch H.A. Improving clinical outcomes in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007, 31(Suppl 3):S7-S9.